^
    Back
    Association details:
    Biomarker:CSF2 expression
    Cancer:Non Small Cell Lung Cancer
    Drug:Opdivo (nivolumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    ASCO 2018
    Title:

    Inflammatory biomarkers for prediction of tumor responses and adverse events in non-small cell lung cancer patients treated with anti-PD-1 inhibitor.

    Published date:
    05/16/2018
    Excerpt:
    Peripheral blood samples were taken from NSCLC patients before nivolumab treatment and every 6-12 weeks from the patients who continued nivolumab treatment...The plasma levels of GM-CSF and Chitinase 3-like-1 before treatment were significant correlated with PFS (P= 0.005 and P= 0.007, respectively).
    DOI:
    10.1200/JCO.2018.36.15_suppl.e21050